Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.
dc.contributor.author | Castellano, Daniel | |
dc.contributor.author | González-Larriba, José L. | |
dc.contributor.author | Antón-Aparicio, Luis M. | |
dc.contributor.author | Cassinello, Javier | |
dc.contributor.author | Grande-Pulido, E. | |
dc.contributor.author | Esteban, Emilio | |
dc.contributor.author | Sepúlveda, Juan | |
dc.date.accessioned | 2024-01-30T09:29:40Z | |
dc.date.available | 2024-01-30T09:29:40Z | |
dc.date.issued | 2011 | |
dc.description.abstract | Objective: Vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) correlate with poor prognosis in castration-resistant prostate cancer (CRPC). Sunitinib has shown activity in CRPC and at the time of this analysis there was no standard therapy for docetaxel-refractory CRPC. Methods: We present a case series data collection of 19 patients with a median age of 73 years, CRPC and rising prostate-specific antigen (PSA). Patients received sunitinib 37.5 mg continuous daily dose. One cycle comprised a 4-week period. Patients were evaluated by CT scan every 8 weeks and PSA was monitored every 4 weeks. Results: Median Eastern Cooperative Oncology Group (ECOG) performance status score was 2. Patients received a median of two previous treatment lines for the hormone-refractory setting. Baseline median PSA was 280 ng/ml. Patients received a median of 16 weeks of therapy (4 – 48+). One patient achieved a partial response (5%) and 12 (66.7%) achieved stable disease for at least 3 months according to RECIST criteria. Median progression-free survival was 4 months. PSA declined > 50% in 5/19 (26.3%) and stabilized in 7/19 (37%) patients. Frequent adverse events were grade 3 asthenia (21%), grade 3 diarrhea (10%) and grade 3 hand-foot syndrome (15.7%). Conclusions: Activity with sunitinib was observed in highly pretreated docetaxel-refractory CRPC with acceptable tolerability. Additional studies should confirm the role of antiangiogenic agents in this setting. | spa |
dc.description.extent | 2,43 MB | spa |
dc.identifier.doi | 10.1517/14656566.2011.590132 | spa |
dc.identifier.issn | 1744-7666 | spa |
dc.identifier.uri | https://hdl.handle.net/10641/3838 | |
dc.language.iso | eng | spa |
dc.publisher | Expert Opinion on Pharmacotherapy | spa |
dc.relation.publisherversion | https://www.tandfonline.com/doi/full/10.1517/14656566.2011.590132 | spa |
dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | * |
dc.rights.accessRights | metadata only access | spa |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.subject | Angiogenesis | spa |
dc.subject | CRPC | spa |
dc.subject | Daily practice | spa |
dc.subject | Prostate cancer | spa |
dc.subject | PSA | spa |
dc.subject | Sunitinib | spa |
dc.title | Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients. | spa |
dc.type | journal article | spa |
dc.type.hasVersion | SMUR | spa |
dspace.entity.type | Publication |